DUBLIN--(BUSINESS WIRE)--(NASDAQ: ICLR) a global provider of drug development services to the pharmaceutical, biotechnology and medical device industries, today announced the release of ADDPLAN® neo, providing an advanced validated integrated technology platform for design, simulation and analysis of adaptive clinical trials.
The new release combines ADDPLAN® BASE, ADDPLAN® MC (for Multiple Comparison Designs) and ADDPLAN® DF (for dose ranging and dose finding trials using MCP-Mod methodology) modules under one umbrella, increasing simulation speed for each application and allowing computation of multiple projects on one, integrated robust framework. The software has been rewritten using C programming language to ensure efficient usage of computing resources and fast simulation results.
Following feedback from customers, ICON enhanced the algorithms’ stability and speed and added new features such as the ability to incorporate custom R code in the ADDPLAN® neo Dose Finding module.
Additional ADDPLAN® neo features include:
Andrew Garrett, EVP Scientific Operations said “With the recent FDA announcement of its Complex Innovative Designs Pilot Meeting Program, targeted at innovative trial designs to inform regulatory decision making, the door is very much open for adaptive and other types of innovative design. ADDPLAN® neo provides an integrated and increasingly flexible solution that truly supports this innovation agenda by providing a validated tool that helps convert theory to practice.”
About ICON plc
ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specializes in the strategic development, management and analysis of programs that support clinical development from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 93 locations in 37 countries and has approximately 13,675 employees.
Further information is available at www.iconplc.com/addplanneo
Contacts
ICON Media Contact
Lucinda Sandon-Allum
Weber Shandwick
+44 (0)20 7067 0548
lsandon-allum@webershandwick.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.